Atara Biotherapeutics To Present Preclinical Data On ATA3219, An Allogeneic CD19-Targeted CAR T Therapy For The Treatment Of B-Cell Driven Autoimmune Diseases, At The ISCT 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics will present preclinical data on ATA3219, an allogeneic CD19-targeted CAR T therapy, at the ISCT 2024 Annual Meeting. ATA3219 shows promising results in depleting CD19-specific B-cells in autoimmune diseases like systemic lupus erythematosus and multiple sclerosis, with lower pro-inflammatory cytokine levels compared to autologous CAR T cells. A Phase 1 study is expected to start in Q4 2024.
May 29, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atara Biotherapeutics will present promising preclinical data on ATA3219, a CD19-targeted CAR T therapy, at the ISCT 2024 Annual Meeting. The data shows effective CD19-specific B-cell depletion and lower pro-inflammatory cytokine levels. A Phase 1 study is expected to start in Q4 2024.
The presentation of promising preclinical data and the initiation of a Phase 1 study in Q4 2024 are positive developments for Atara Biotherapeutics. These milestones could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100